Atlas Trials

Glabellar Lines

49 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Glabellar Lines

RecordFirmDate
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines (NCT05428930)CKD Bio Corporation2022-06-22
Phase 2 of HU-045 in Glabellar Lines (NCT05298449)Huons Co., Ltd.2022-03-28
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines (NCT05248867)AbbVie2022-03-16
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines (NCT05248880)AbbVie2022-03-08
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines (NCT05248893)AbbVie2022-02-25
Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines (NCT05292638)CKD Bio Corporation2022-02-15
Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin (NCT05089357)Galderma R&D2021-11-11
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines (NCT05100199)Allergan2021-10-06
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines (NCT05013424)Allergan2021-09-01
To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines. (NCT04944953)Hugel2021-06-11
Treatment of Moderate to Severe Glabellar Lines (BMI2006) (NCT05531968)BMI Korea2021-02-09
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines (NCT04225260)Galderma R&D2020-01-27
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) (NCT04157686)Medy-Tox2019-10-23
MT10109L in the Treatment of Glabellar Lines (NCT03795922)Medy-Tox2018-12-24
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines (NCT03732833)Medy-Tox2018-11-05
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) (NCT03721016)Medy-Tox2018-10-26
Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines. (NCT05380154)Hugel2017-05-09
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines (NCT02961673)Huons Co., Ltd.2016-09-01
Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines (NCT02718118)Galderma R&D2016-04-01
Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines (NCT03216408)Medy-Tox2016-03-30
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines (NCT02493946)Ipsen2015-04-01
Dysport in the Treatment of Glabellar Lines in Chinese Subjects (NCT02450526)Ipsen2015-04-01
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport® (NCT02353897)Ipsen2014-10-01
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study) (NCT02176356)Allergan2014-06-30
BOTOX® in the Treatment of Upper Facial Lines in Japan (NCT01797094)Allergan2013-02-01
Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX® (NCT01608672)Allergan2012-04-01
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines (NCT01224015)Allergan2011-05-01
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines (NCT01271452)Allergan2010-09-01
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines (NCT01189760)Allergan2010-09-01
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea (NCT02043145)Allergan2008-07-01
A Study Of BOTOX For The Treatment Of Glabellar Lines (NCT00408785)GlaxoSmithKline2006-11-01

Track Glabellar Lines automatically

Every clearance here is in the API, with alerts when new ones post.